Nivolumab plus ipilimumab (N+I) in patients (pts) with ovarian cancer (OC) with BRCA1/2 mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
Year: 2023
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Charles Drescher, Michael Rothe, Pam K. Mangat, Elizabeth Garrett-Mayer, Deepti Behl, Eugene R Ahn, Tareq Al Baghdadi, R. Wendel Naumann, Maria C Bell, Charles A. Leath, Timothy Lewis Cannon, Olatunji B. Alese, Gina N. Grantham, Abigail Gregory, Dominique C. Hinshaw, Susan Halabi, Richard L. Schilsky
Institutions: American Society of Clinical Oncology, Sutter Medical Center, Cancer Treatment Centers of America, Michigan Cancer Research Consortium, Levine Cancer Institute, Sanford Health, University of Alabama at Birmingham, O'Neal Comprehensive Cancer Center, Inova Fairfax Hospital, Winship Cancer Institute, Duke Medical Center
Language: English
Subfield: Genetics
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W4379281762